Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04552288 · ClinicalTrials.gov registry record · Phase 2

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

A Phase 2 study of Solid Tumor and Solid Tumor, Adult, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
51
Enrollment target
5
Study locations

NCT04552288 is a Phase 2 study of Solid Tumor and Solid Tumor, Adult that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 51 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 5 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04552288, a Phase 2 study of Solid Tumor and Solid Tumor, Adult, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
51 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

Conditions Studied

Solid Tumor Solid Tumor, Adult Hematologic Malignancy Solid Carcinoma

Interventions

  • DRUG Benralizumab

Study Locations (5)

New York

  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities) - Hauppauge
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York

New Jersey

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2020-09-16
Est. Completion 2026-03-16
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04552288

The ClinicalTrials.gov registry entry for NCT04552288 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.

NCT04552288 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04552288 about?

NCT04552288 is a clinical study titled "Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies". The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life an...

What is the current status of trial NCT04552288?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-09-16. Estimated completion is 2026-03-16.

What conditions does trial NCT04552288 study?

This clinical trial studies the following conditions: Solid Tumor, Solid Tumor, Adult, Hematologic Malignancy, Solid Carcinoma.

What interventions are being tested in trial NCT04552288?

The interventions under investigation include: Benralizumab (DRUG).

Who is sponsoring clinical trial NCT04552288?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04552288 being conducted?

This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Solid Tumor, Adult

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.